Send the latest investment ideas directly to your inbox. subscription

The distributor of the proprietary product placed the third large order.

Avivagen Inc. (VIV:TSX.V) announced in a press release that it has just sold 2 metric tons (2 mT) of OxC-beta Livestock to UNAHCO, the exclusive distributor of life sciences products in the Philippines.

"UNAHCO reiterated its intention to purchase OxC-beta Livestock every quarter, which has become a growing and recurring source of revenue for Avivagen," the press release stated. The product is now registered in the Philippines and can be used for all animals that eat feed, mainly pigs and broilers. The company noted that it has proven to be an effective and economical alternative to common antibiotics in livestock feed.

With this order, UNAHCO has purchased 7.2 metric tons so far this year, and 9.1 metric tons have been purchased since the first purchase in November 2016.

Avivagen noted that it continues to accelerate the adoption of its OxC-beta Livestock product. Together with the Philippines, it is currently registered and available for purchase in Taiwan, Thailand and New Zealand.

Read comments from other experts:

Disclosure: 1) Doresa Banning wrote this article for Streetwise Reports LLC and provided services to Streetwise Reports as an independent contractor. She or her family members own the securities of the following companies mentioned in the article: None. Her or her family members are paid by the following companies mentioned in this article: None. 2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures regarding sponsor fees. As of the publication date of this article, a subsidiary of Streetwise Reports has established a consulting relationship with Avivagen. Please click here for more information. 3) The comments and opinions expressed are those of specific experts, not those of Streetwise Reports or its officials. The information provided above is for reference only and is not a recommendation to buy or sell any securities. 4) This article does not constitute investment advice. We encourage each reader to consult his or her personal financial professional, and any action taken by the reader based on the information provided is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and complete legal disclaimer. This article is not about investment promotion. Streetwise Reports does not provide general or specific investment advice, and the information on Streetwise Reports should not be regarded as a recommendation to buy or sell any securities. Streetwise Reports does not endorse or recommend any company's business, products, services or securities mentioned in Streetwise Reports. 5) Sometimes, Streetwise Reports LLC and its directors, officers, employees or their family members, as well as people interviewed for articles and interviews on the website, may hold long or short positions in the aforementioned securities. Directors, officers, employees or their immediate family members are prohibited from buying and/or selling these securities on the open market or by other means, starting from the interview or deciding to write an article, and ending with the interview or article three working days after publication. The above prohibition does not apply to essentially only restating articles published by the company previously published. As of the publication date of this article, the managers and/or employees of Streetwise Reports LLC (including their family members) own the securities of the Avivagen company mentioned in this article.

Novavax shares rose 65% in the 89.3% effectiveness of the Phase 3 COVID-19 vaccine trial Source: Streetwise Reports (01/29/2021)

Novavax Inc.’s stock price hit a 52-week high after the company’s COVID-19 vaccine showed an 89.3% effectiveness in the Phase 3 trial in the UK and showed its efficacy against the South African variant in the Phase 2b trial.

After the company released positive data from Phase 1b of the ICU COVID-19 trial, Sorrento’s share price rose by 35%. Source: Streetwise Reports (01/27/2021)

After Sorrento Therapeutics released the positive preliminary results of its Phase 1b COVI-MSC ™ study for the treatment of inpatient ICU patients with COVID-19, its stock price rose.

The life science company receives a large livestock feed order from a new customer in Mexico. Source: Streetwise Reports (01/27/2021)

Avivagen Inc. reports that it has received a 6-ton OxC-beta™ Livestock order from a new customer in Querétaro, Mexico.

Source of report on biotechnology "improving drugs through prodrugs": Streetwise Reports (01/27/2021)

A report by ROTH Capital Partners discussed KemPharm’s key near-term catalysts, leading value drivers, and other pipeline drug candidates.

Vir's stock price climbed 48% during the initial phase of the first phase of the chronic hepatitis B trial. Source: Streetwise Reports (01/26/2021)

Vir Biotechnology's stock price rose after the company reported data from its phase 1 chronic hepatitis B study, which showed that VIR-3434 significantly and rapidly reduced the hepatitis B surface antigen.

With the FDA's approval of adult lupus nephritis drugs, Aurinia Pharma's stock price opened to a new 52-week high. Source: Streetwise Reports (01/25/2021)

Aurinia Pharmaceuticals shares rose 30% after the company reported that the US Food and Drug Administration approved its LUPKYNIS™ (vorosporin) for the treatment of adult active lupus nephritis.

AzurRx was administered to the first two people in an extended phase 2b trial in patients with cystic fibrosis Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma's stock price rose 45% after the company said that it had administered drugs to the first two patients in the Phase 2b OPTION 2 expansion study of MS1819 to treat exocrine pancreatic insufficiency in patients with cystic fibrosis.

Gritstone Oncology authorized the LNP platform from Genavent Sciences to develop COVID-19 vaccine Source: Streetwise Reports (01/20/2021)

Gritstone Oncology’s stock price reached a 52-week high after the company suggested that it sign a non-exclusive license agreement with Geneva Science to develop and commercialize a self-amplified RNA vaccine against SARS-CoV-2.

Biotech company is approved to proceed with Phase 3 COVID-19 research Source: Streetwise Reports (01/20/2021)

Algernon Pharmaceuticals reports that it has received approval from the Data and Safety Monitoring Committee to conduct the Phase 3 study of SARS-CoV-2 on Ifenprodil.

Aclaris has tripled its value in the positive top-line data of the Phase 2a Rheumatoid Arthritis Trial. Source: Streetwise Reports (01/19/2021)

Aclaris Therapeutics Inc.'s stock price soared to a 52-week high after the company reported positive preliminary top-line data from its Phase 2a trial of oral ATI-450 for the treatment of moderate to severe rheumatoid arthritis.

Founded by the same team that brought you Streetwise Reports.

Novavax stock price rises 65% due to 89.3% effectiveness of COVID-19 vaccine Phase 3 trial

Sorrento shares rose 35% after the company released positive data from the 1b ICU COVID-19 trial

Life Sciences Co. received a large livestock feed order from a new customer in Mexico

Report on Biotechnology "Improving Drugs Through Prodrugs"

Vir stock price climbs 48% on initial phase 1 chronic hepatitis B trial data

With FDA approval of adult lupus nephritis drugs, Aurinia Pharma's stock price opened to a new 52-week high

AzurRx is administered to the first two people in an extended phase 2b trial of patients with cystic fibrosis

Gritstone Oncology authorizes the LNP platform from Genavent Sciences to develop a COVID-19 vaccine

Biotech company approved to continue Phase 3 COVID-19 research

Aclaris shared three times the value of positive top-line data from the Phase 2a rheumatoid arthritis trial

© 2021 Street report. all rights reserved.

Streetwise Reports is registered in the United States Patent and Trademark Office.